Camurus AB Cash Flow | StatInvestor

Health Care & Life Sciences » Pharmaceuticals | Camurus AB

Camurus AB | Cash Flow

Fiscal year is January-December. All values SEK Thousands.

2013

2014

2015

2016

2017

2018

Net Income before Extraordinaries

127,316.00

62,319.00

204,104.00

102,452.00

243,524.00

287,218

Depreciation, Depletion & Amortization

814.00

1,427.00

3,552.00

3,524.00

4,088.00

2,368

Other Funds

114,616.00

1,960

Funds from Operations

128,082.00

64,007.00

91,606.00

109,752.00

239,264.00

282,890

Changes in Working Capital

34,982.00

5,422.00

85,949.00

98,036.00

36,196.00

8,806

Net Operating Cash Flow

163,064.00

69,429.00

5,657.00

207,788.00

203,068.00

274,084

Capital Expenditures

14,831.00

7,198.00

1,339.00

4,567.00

2,143.00

Purchase/Sale of Investments

33,615.00

87,244.00

158,314.00

Net Investing Cash Flow

48,446.00

94,442.00

156,975.00

4,567.00

2,143.00

Net Financing Cash Flow

114,616.00

25,064.00

564,722.00

4,853.00

11,141.00

Net Change in Cash

2.00

51.00

716,040.00

207,502.00

194,070.00

Free Cash Flow

161,535.00

64,059.00

6,641.00

212,355.00

205,211.00

Change in Capital Stock

25,064.00

564,722.00

4,853.00

11,141.00

About Camurus AB

View Profile

Address	Ideon Science Park Lund SN 223 70 Sweden
Employees	-
Website	http://www.camurus.com
Updated	07/08/2019
Camurus AB engages in the research, development, and commercialization of specialty medicines. It provides its products for the treatment of severe and chronic conditions, which includes opioid dependence, pain, cancer, and endocrine disorders. The company was founded by Kare Larsson in 1991 and is headquartered in Lund, Sweden.